Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

47
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
47
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

108
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
108
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

76
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
76
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

60
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
60
Angina IV: Management01:26

Angina IV: Management

44
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
44
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

29
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of <sup>15</sup>O-water PET global myocardial flow reserve: Proposed risk-based cutoffs.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

Analytical Performance Evaluation of the Cardiac Troponin T High Sensitivity Gen 6 Assay.

The journal of applied laboratory medicine·2026
Same author

Evaluation of Gd-DOTA as a marker for myocardial blood flow using <sup>68</sup>Ga-DOTA and <sup>15</sup>O-water positron emission tomography.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study.

Clinical chemistry·2026
Same author

Clinical performance of the next generation Elecsys Troponin T high-sensitivity Gen 6 assay in acute coronary syndrome (PERFORM-TSIX): study design.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Predictors of depressed left-ventricular ejection fraction after acute myocardial infarction.

International journal of cardiology·2025

Related Experiment Video

Updated: Oct 8, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.8K

Risk-associated management disparities in acute myocardial infarction.

Kai M Eggers1, T Jernberg2, B Lindahl3

  • 1Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, 751 85, Uppsala, Sweden. kai.eggers@ucr.uu.se.

Scientific Reports
|December 30, 2021
PubMed
Summary

Management of high-risk myocardial infarction (MI) patients is improving, but disparities persist. High-risk individuals receive fewer interventions and less follow-up, necessitating continuous quality improvement initiatives for equitable care.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

11.9K

Related Experiment Videos

Last Updated: Oct 8, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.8K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

11.9K

Area of Science:

  • Cardiology
  • Public Health
  • Health Services Research

Background:

  • Despite advances in myocardial infarction (MI) treatment, potential disparities in care based on patient risk stratification persist.
  • The GRACE 2.0 score is a validated tool for assessing MI patient risk, guiding clinical decisions.
  • Temporal trends in the management of MI patients across different risk strata require ongoing investigation.

Purpose of the Study:

  • To investigate temporal trends in the management of myocardial infarction (MI) patients stratified by risk using the GRACE 2.0 score.
  • To identify potential disparities in the utilization of coronary procedures, pharmacological treatments, and secondary prevention strategies among high-risk MI patients compared to lower-risk groups.
  • To evaluate changes in care patterns over time and identify areas for quality improvement.

Main Methods:

  • Analysis of a large myocardial infarction (MI) cohort (n=179,291) from the SWEDEHEART registry (2005-2017).
  • Utilized multivariable models to assess associations between GRACE 2.0 risk categories and interventions (reperfusion, invasive assessment, revascularization).
  • Examined temporal trends in pharmacological treatments (P2Y12-blockers, betablockers, RAAS-inhibitors, statins) and secondary prevention (smoking cessation, exercise training).

Main Results:

  • High-risk MI patients (42.6%) received fewer interventions than lower-risk patients, except for betablocker treatment.
  • Overall intervention rates increased over time, with greater increases in high-risk patients for revascularization and P2Y12-blocker use.
  • Temporal increases were less pronounced in high-risk patients for RAAS-inhibitor prescription and structured follow-up, indicating persistent management gaps.

Conclusions:

  • While the management of high-risk MI patients shows improvement, significant disparities remain, particularly concerning RAAS-inhibitor use and structured follow-up.
  • The study highlights the need for continuous quality improvement initiatives to ensure equitable and optimal care for all MI patients, regardless of risk level.
  • Addressing these identified gaps is crucial for reducing adverse outcomes and improving long-term prognosis in high-risk myocardial infarction populations.